Astrazeneca (AZN) Market Capitalization (2009 - 2026)

Astrazeneca has reported Market Capitalization for 18 years, with the latest figure at $293.9 billion in Q2 2026.

• On a quarterly basis, Market Capitalization rose 35.68% year-over-year to $293.9 billion in Q2 2026; TTM through Jun 2026 was $293.9 billion, a 35.68% increase from a year earlier, with the FY2025 full-year figure at $285.0 billion, up 40.31% from the prior year.
• Market Capitalization was $293.9 billion for Q2 2026 at Astrazeneca, down from $305.7 billion in the prior quarter.
• The five-year high for Market Capitalization was $305.7 billion in Q1 2026, with the low at $169.9 billion in Q3 2022.
• Average Market Capitalization over 5 years is $228.2 billion, with a median of $215.8 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Market Capitalization soared 57.57% in 2022, then retreated 10.34% in 2025.
• Over 5 years, Market Capitalization stood at $209.9 billion in 2022, then declined by 0.6% to $208.7 billion in 2023, then dropped by 2.65% to $203.1 billion in 2024, then jumped by 40.31% to $285.0 billion in 2025, then rose by 3.13% to $293.9 billion in 2026.
• The last three Market Capitalization figures came in at $293.9 billion (Q2 2026), $305.7 billion (Q1 2026), and $285.0 billion (Q4 2025), per Business Quant data.